The Bill and Melinda Gates Foundation has committed $5.7 million for the fight against the deadly Ebola virus disease.
The foundation has decided to support efforts in Guinea and other Ebola-affected countries to scale up the production and evaluation of convalescent plasma and other convalescent blood products as potential therapies for people infected with the Ebola virus.
Various drug candidates will also be evaluated, including the experimental antiviral drug Brincidofovir, the foundation said Tuesday in a statement.
The programme will focus on treatments derived from the blood of survivors.
"The grant will also be used to evaluate new experimental drugs for Ebola," said a statement issued by the foundation.
More than 5,000 people have died in the current Ebola outbreak -- almost all of them in West Africa.
There is currently no licensed treatment or vaccine for the Ebola virus. Hospital treatment is based on giving patients intravenous fluids to stop dehydration and antibiotics to fight infections.
There are however several experimental vaccines and drug treatments for Ebola under development, but these have not yet been fully tested for safety or effectiveness.
International medical humanitarian organisation Medecins Sans Frontieres (MSF) had announced last week that it would host clinical trials in three Ebola treatment centres in West Africa in December.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
